151 related articles for article (PubMed ID: 38048850)
1. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
[TBL] [Abstract][Full Text] [Related]
2. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
[TBL] [Abstract][Full Text] [Related]
3. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
[TBL] [Abstract][Full Text] [Related]
5. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS; Poretta T; Stwalley BD; Sakkal LA; Du EX; Wang T; Chen Y; Wang Y; Betts KA; Shoushtari AN
Cancer Immunol Immunother; 2023 Apr; 72(4):945-954. PubMed ID: 36197494
[TBL] [Abstract][Full Text] [Related]
7. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
8. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution.
Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA
Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment for stage III and IV cutaneous melanoma.
Gorry C; McCullagh L; O'Donnell H; Barrett S; Schmitz S; Barry M; Curtin K; Beausang E; Barry R; Coyne I
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012974. PubMed ID: 36648215
[TBL] [Abstract][Full Text] [Related]
11. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
13. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G
Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
Pelster MS; Gruschkus SK; Bassett R; Gombos DS; Shephard M; Posada L; Glover MS; Simien R; Diab A; Hwu P; Carter BW; Patel SP
J Clin Oncol; 2021 Feb; 39(6):599-607. PubMed ID: 33125309
[TBL] [Abstract][Full Text] [Related]
15. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.
Hamid O; Hassel JC; Shoushtari AN; Meier F; Bauer TM; Salama AKS; Kirkwood JM; Ascierto PA; Lorigan PC; Mauch C; Orloff M; Evans TRJ; Holland C; Edukulla R; Abedin SE; Middleton MR
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286303
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal: ORIGINAL ARTICLE: Wolchok JD, Chiarion-Sileni V, Gonzalez R et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2017; 377:1345-56.
Wan MT; Ming ME
Br J Dermatol; 2018 Aug; 179(2):296-300. PubMed ID: 29766492
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
18. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; Ciuleanu TE; Schenker M; Cobo M; Bordenave S; Juan-Vidal O; Menezes J; Reinmuth N; Richardet E; Cheng Y; Mizutani H; Felip E; Zurawski B; Alexandru A; Paz-Ares L; Lu S; John T; Zhang X; Mahmood J; Hu N; De T; Santi I; Penrod JR; Yuan Y; Lee A; Reck M
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38346853
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients.
Salaün H; de Koning L; Saint-Ghislain M; Servois V; Ramtohul T; Garcia A; Matet A; Cassoux N; Mariani P; Piperno-Neumann S; Rodrigues M
Oncoimmunology; 2022; 11(1):2116845. PubMed ID: 36092639
[TBL] [Abstract][Full Text] [Related]
20. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]